Although the variety of FASN inhibitors developed in recent years (e.g., C75, C93, C246, FAS31, Orlistat, triclosan, GSK837149A) has consistently demonstrated preclinical activity in cultured cancer cell lines and xenograft models, none of these compounds have been tested in cancer patients because of limitations imparted by their pharmacological properties (e.g., poor cell permeability, poor oral bioavailability and lack of selectivity) or side-effect profiles (e.g., anorexia and weight-loss), which could be limiting in the development of cancer therapy [41–43]. The gene discussed is FASN; the disease is cancer.